Zhu W, et al. - In esophageal squamous cell carcinoma (ESCC) patients, researchers assessed ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) as a tool for the prediction of clinical response of metastatic lymph node (mLN) to definitive chemoradiotherapy (dCRT) and guide tailored radiation. They examined 143 mLNs from 59 patients with ESCC treated with dCRT and who had undergone a pretreatment ¹⁸F-FDG-PET/CT scan. They found that for patients with ESCC, the response of mLNs to dCRT could be predicted by pretreatment metabolic parameters. Moreover, the parameters could also be used to guide personalized dose to mLNs.